[1] Igene H.Global health inequalities and breast cancer:an impending public health problem for developing countries[J].Breast J,2008,14(5):428-434.
[2] Onitilo AA,Engel JM,Greenlee RT.Breast cancer subtypes based on ER/PR and Her2 expression:comparison of clinicopathologic features and survival[J].Clin Med Res,2009,7(1/2):4-13.
[3] Milani A,Geuna E,Mittica G,et al.Overcoming endoccrine resistance in metastatic breast cancer:Current evidence and future directions[J].World J Clin Oncol,2014,5(5):990-1001.
[4] Patel RR,Sharma CG,Jordan VC.Optimizing the antihormonal treatment and prevention of breast cancer[J].Breast Cancer,2007,14(2):113-122.
[5] 张厚云,赵凌云.乳腺癌内分泌治疗研究进展[J].中国普通外科杂志,2014,23(5):680-684.
[6] 朱 歌.曲妥珠单抗联合NK细胞对乳腺癌细胞体外杀伤作用的实验研究[D].长春:吉林大学,2014.
[7] 董 营.表柔比星序贯NK细胞体外杀伤乳腺癌细胞的研究[D].长春:吉林大学,2015.
[8] Feng H,Dong Y,Wu J,et al.Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitro [J].Am J Translat Res,2016,8(2):473.
[9] Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[10] Pagani O,Regan MM,Francis PA.Are SOFT and TEXT results practice changing and how?[J].Breast,2016,27:122-125.
[11] Salami S,Karami-Tehrani F.Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines[J].Clin Biochem,2003,36(4):247-253.
[12] Metah A, Tripathy D.Co-targeting estrogen receptor and HER2 pathways in breast cancer[J].Breast,2014,23(1):2-9.
[13] Musgrove EA,Sutherland RL.Biological determinants of endocrine resistance in breast cancer[J].Nat Rev Cancer,2009,9(9):631-643.
[14] Ellis MJ,Coop A,Singh B,et al.Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive,estrogen receptor-positive primary breast cancer:evidence from a phase Ⅲ randomized trial[J].J Clin Oncol,2001,19(18):3808-3816.
[15] Ellis MJ,Tao Y,Young O,et al.Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole[J].J Clin Oncol,2006,24(19):3019-3025.
[16] Lanier LL.NK cell recognition[J].Annu Rev Immunol,2005,23:225-274.
[17] 王 鹏,李 玲,阚全程,等.表达US3基因腺病毒载体下调CTL和NK细胞对其转染肝细胞杀伤活性的影响[J].西安交通大学学报:医学版,2015,36(5):655-660.
[18] 吴朝真,刘 放,李 宁.Fractalkine、IP-10及不同信号通路抑制剂对肿瘤微环境中NK细胞的影响[J].解放军医学杂志,2015,40(7):547-553.
[19] Wang W,Erbe AK,Hank JA,et al.NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy[J].Front Immunol,2015,6:368.
[20] 闫振北,韩明强.雌激素水平影响他莫昔芬抑制乳腺癌细胞生长的机制探讨[J].中国医刊,2008,43(1):57-58.
[21] Chang E,Rosenberg SA.Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy[J].J Immunother,2001,24(1):88-90.
[22] 高德宗,孙靖中,高 华,等.γ-干扰素增强他莫昔芬抗乳腺癌作用的体外研究[J].中国肿瘤生物治疗杂志,2006,13(1):45-49.
[23] 张巧利,李 芬,吕淑兰,等.乳腺密度、性激素补充治疗与乳腺癌的关系[J].中国老年学杂志,2015,35(17):5012-5016. |